Evidence map›Paper›PMID 28492521›Full record

ArticleGene therapy2017

Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.

Y Sun, S Peng, A Yang, E Farmer, T-C Wu, C-F Hung

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Biomaterials for vaccine-based cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Review
  10. Article
  11. The γF1000Research · 2017
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Y SunDepartment of Obstetrics and Gynecology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
S PengDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
A YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
E FarmerDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
T-C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
C-F HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Johns Hopkins University · USShanghai First People's Hospital · CN

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259
6 · The paper itself

Abstract

The generation and use of therapeutic human papillomavirus (HPV) DNA vaccines represent an appealing treatment method against HPV-associated cervical cancer owing to their safety and durability. Previously, we created a therapeutic HPV DNA vaccine candidate by linking the HPV16-E7 DNA sequence to calreticulin (CRT/E7), which we showed could generate significant E7-specific cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against HPV16 oncogenes expressing murine tumor model TC-1. Here we assess the therapeutic efficacy of intravaginal immunization with pcDNA3-CRT/E7 followed by electroporation. In addition, we examined whether coadministration of DNA-encoding interleukin 2 (IL2) with the pcDNA3-CRT/E7 could improve the T-cell responses elicited by pcDNA3-CRT/E7. TC-1 tumor-bearing mice vaccinated intravaginally with both pcDNA3-CRT/E7 and IL2 DNA followed by electroporation induced stronger local antitumor CTL response in comparison to mice that received other treatment regimens. Additionally, we found that coadministration of IL2 DNA with pcDNA3-CRT/E7 modified the tumor microenvironment by decreasing the population of regulatory T cells and myeloid-derived suppressor cells relative to that of CTLs. Our data demonstrate the translational potential of local administration of IL2 and pcDNA3-CRT/E7 followed by electroporation in treating cervicovaginal tumors.

Indexed as

Administration, IntravaginalAnimalsCalreticulinCell Line, TumorCells, CulturedElectroporationFemaleInterleukin-2MaleMiceMice, Inbred C57BLPapillomavirus InfectionsPapillomavirus VaccinesT-Lymphocytes, CytotoxicUterine Cervical NeoplasmsVaccines, DNACalreticulinInterleukin-2Papillomavirus VaccinesVaccines, DNA

Identifiers

PMID28492521
PMCPMC5510480
OpenAlexW2613119074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.